Migraine - Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-12-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

After the launch of Trexima in 2007, triptan genericization coupled with a weak late-stage pipeline will result in a major shift in market dynamics, and will result in the migraine market value decreasing to $3.2 billion in 2015. The market remains receptive to superior prophylactics however, with innovation being essential for the progression of the acute market, post-triptan era.


Scope

  • Analysis of patient potential, unmet needs and clinical trial design in migraine
  • Overview of drugs in preregistration, Phase III, II and I; with analysis of key companies involved in the R&D pipeline
  • Detailed profiles of key compounds in development for use in migraine, with forecasts of drug revenues to 2015
  • Discussion of GSK and Pozen's strategies and insight from key industry opinion leaders


    • Report Highlights
    Due to Imitrex's commercial success, GSK is the current migraine market leader. Trexima, co-developed by GSK and Pozen represents GSK's product line extension for its migraine franchise, but approval delays and the impending US sumatriptan patent expiry will limit its success.

    The next big thing in the prophylactic market will be the label expansion of Allergan's Botox and Ipsen's Dysport. Seven major market Botox and Dysport combined sales for migraine are forecast to grow to over $170m in 2015.

    The presence of glutamatergic receptor inhibitors, NOS inhibitors and CGRP antagonists, amongst others in early stage clinical trials, indicate companies are developing innovative drugs for the post triptan future. With all identified to play a role in the biological mechanisms of migraine, there holds great potential in such novel drug targets.


    Reasons to Purchase

  • Understand unmet needs in the migraine market based on key opinion leader comments
  • Benchmark key late-stage migraine compounds against current market leaders
  • Assess the combined US, Japan, five major EU sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential

    • Table of Contents

    Other users found this report page using the following search terms: migraine triptan tezampanel trexima use therapeutic patent discontinued 0974 mk sb705498 ast726

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.